ABVC BioPharma (NASDAQ:ABVC) Issues Earnings Results

ABVC BioPharma (NASDAQ:ABVC) announced its quarterly earnings data on Tuesday. The company reported $0.04 earnings per share for the quarter, Zacks reports. ABVC BioPharma had a negative return on equity of 104.94% and a negative net margin of 1,619.65%.

ABVC BioPharma Stock Performance

NASDAQ:ABVC traded down $0.02 during trading hours on Tuesday, reaching $0.90. The company’s stock had a trading volume of 154,962 shares, compared to its average volume of 405,562. ABVC BioPharma has a 1 year low of $0.40 and a 1 year high of $1.73. The firm has a 50-day simple moving average of $0.72 and a 200-day simple moving average of $0.61. The firm has a market capitalization of $11.62 million, a price-to-earnings ratio of -1.04 and a beta of 0.33.

ABVC BioPharma Company Profile

ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients.